Sutro Biopharma
Sutro Biopharma is a clinical-stage biotechnology company in South San Francisco, California, specializing in drug discovery, development, and manufacturing with a focus on antibody-drug conjugates and bispecific antibodies.
Company Overview
Sutro Biopharma is a clinical-stage biotechnology company engaged in drug discovery, development, and manufacturing. The company is headquartered in South San Francisco, California. Sutro Biopharma's expertise lies in developing innovative therapies using their proprietary technology platforms, XpressCF® and XpressCF+®, which enable cell-free protein synthesis and site-specific conjugation.
Technology Platform
Sutro Biopharma uses its proprietary technology platforms, XpressCF® and XpressCF+®, to expedite the discovery and development of protein therapeutics. These platforms allow for rapid protein synthesis and site-specific conjugation, facilitating the creation of advanced therapies such as antibody-drug conjugates (ADCs) and bispecific antibodies. The company's technology is designed to optimize and accelerate the engineering of proteins for therapeutic purposes.
Clinical Pipeline
Sutro Biopharma has several candidates in clinical stages, focusing on diseases such as ovarian cancer, endometrial cancer, and non-small cell lung cancer. One of the company's leading candidates is luveltamab tazevibulin (luvelta), a folate receptor alpha (FolRα)-targeting ADC currently in the REFRαME-O1 trial. This trial is a global registration-directed study for treating platinum-resistant ovarian cancer. Luvelta has received Fast Track designation from the FDA, highlighting its potential in treating this severe condition.
Collaborations and Partnerships
Sutro Biopharma has established strategic collaborations with notable companies such as Merck, Tasly Biopharmaceuticals, Astellas, and Ipsen. These partnerships aim to leverage Sutro's technology to develop innovative therapeutics across various disease areas. The collaborations enhance Sutro's ability to optimize and bring new treatments to the market efficiently.
Commitment to Sustainability and Community
Sutro Biopharma demonstrates a strong commitment to environmental sustainability, having achieved Silver LEED certification for its headquarters in South San Francisco. The company also emphasizes diversity, equity, inclusion, and belonging (DEIB) within its corporate culture. Recognition by BioSpace as one of the 'Best Places to Work' underscores Sutro Biopharma's dedication to creating a positive and inclusive work environment.